Physician profile
Robert Wright Higginbotham
NPI 1609878834
$2,720.45
in general payments reported to CMS, 2019-2025
18 companies · $551 in 2025
The $551 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $604 · 2020: $295 · 2021: $313 · 2022: $257 · 2023: $431 · 2024: $270 · 2025: $551.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,251.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,251.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $1,145.41 | 2019-2025 | Clareon, Argos, Lensx |
| Sight Sciences, INC. | $282.90 | 2021-2022 | |
| Bausch & Lomb Americas INC. | $233.27 | 2024-2025 | Miebo, Xiidra |
| Glaukos Corporation | $156.60 | 2025 | |
| Ivantis, INC | $148.36 | 2019 | |
| Sun Pharmaceutical Industries INC. | $133.94 | 2019-2023 | Cequa |
| Aerie Pharmaceuticals, INC. | $115.02 | 2021 | |
| Dompe US, INC. | $88.98 | 2021-2025 | Oxervate |
| Carl Zeiss Meditec, INC. | $76.37 | 2019 | |
| Oyster Point Pharma, INC. | $69.23 | 2023-2025 | Tyrvaya, Ryzumvi |
| Amgen INC. | $54.14 | 2024-2025 | Tepezza |
| Tarsus Pharmaceuticals, INC. | $50.78 | 2024-2025 | Xdemvy |
| Novartis Pharmaceuticals Corporation | $42.87 | 2019 | |
| Optos, INC. | $40.67 | 2020 | |
| Allergan, INC. | $25.49 | 2020 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb, A Division of Bausch Health US, LLC | $19.85 | 2020 | |
| Rxsight INC | $18.95 | 2022 | |
| Horizon Therapeutics Plc | $17.62 | 2023 | Tepezza |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Higginbotham listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.